Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Position Increased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. boosted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 27.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,531 shares of the biotechnology company’s stock after buying an additional 4,238 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Arrowhead Pharmaceuticals were worth $598,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Washington Trust Advisors Inc. acquired a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $25,000. Fifth Third Bancorp lifted its stake in Arrowhead Pharmaceuticals by 112.0% during the third quarter. Fifth Third Bancorp now owns 988 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. Friedenthal Financial bought a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth approximately $51,000. Van ECK Associates Corp grew its position in Arrowhead Pharmaceuticals by 22.9% in the fourth quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company’s stock worth $73,000 after buying an additional 447 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Arrowhead Pharmaceuticals by 96.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,753 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 1,352 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ARWR shares. Morgan Stanley raised their price objective on Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 7th. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, February 8th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 7th. Finally, Citigroup boosted their price target on shares of Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the company a “neutral” rating in a report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.80.

Arrowhead Pharmaceuticals Stock Up 0.9 %

Shares of Arrowhead Pharmaceuticals stock traded up $0.22 on Wednesday, hitting $25.22. 906,027 shares of the company traded hands, compared to its average volume of 1,394,640. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $20.67 and a 12-month high of $41.28. The company has a market cap of $3.12 billion, a PE ratio of -9.07 and a beta of 0.78. The company has a 50-day moving average price of $26.93 and a 200 day moving average price of $28.72.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, February 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.46). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 90.77%. The firm had revenue of $3.55 million during the quarter, compared to analysts’ expectations of $35.60 million. During the same quarter last year, the firm earned ($0.39) EPS. The business’s revenue for the quarter was down 94.3% compared to the same quarter last year. Equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.7 EPS for the current year.

Insider Activity

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu acquired 1,000 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was purchased at an average cost of $27.49 per share, for a total transaction of $27,490.00. Following the completion of the acquisition, the director now owns 31,680 shares of the company’s stock, valued at approximately $870,883.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Arrowhead Pharmaceuticals news, Director Hongbo Lu purchased 1,000 shares of the stock in a transaction dated Monday, March 18th. The shares were bought at an average cost of $27.49 per share, with a total value of $27,490.00. Following the completion of the transaction, the director now owns 31,680 shares in the company, valued at approximately $870,883.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kenneth Allen Myszkowski sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $35.19, for a total value of $1,407,600.00. Following the completion of the sale, the chief financial officer now directly owns 400,600 shares in the company, valued at approximately $14,097,114. The disclosure for this sale can be found here. 4.50% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.